Hepatitis C Treatments
Find Hepatitis C Treatments
Brand Name
Mavyret
Generic Name
Glecaprevir
View Brand Information FDA approval date: August 03, 2017
Classification: Hepatitis C Virus NS3/4A Protease Inhibitor
Form: Pellet, Tablet
What is Mavyret (Glecaprevir)?
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis . MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor , but not both [see Dosage and Administration.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder
Summary: A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
The Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
Summary: This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not ...